Phase III ARAMIS Trial Darolutamide in Patients with Non-metastatic Castration-resistant Prostate Cancer Meets Primary Endpoint - Tom Keane

(Length of video: 5 min)

Tom Keane, MBBCh, FRCSI, FACS provides highlights of the recent press release of ARAMIS, a phase III trial of darolutamide in patients with non-metastatic castrate-resistant prostate cancer. Darolutamide significantly extended metastasis-free survival compared to placebo, meeting its primary endpoint. The safety profile and tolerability of darolutamide observed in the ARAMIS trial were consistent with previously published data. Bayer has been granted Fast Track designation by the FDA.

Biographies:

Thomas E. Keane, MBBCh, FRCSI, FACS

E-Newsletters

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.

Subscribe